Table 12 (abstract O41). Base line characteristics
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Variables | Placebo | One alpha | Risedronate | All patients |
|---|---|---|---|---|
N | 77 | 71 | 69 | 217 |
Age (years), Mean (SD) | 12.1 (3.5) | 12.1 (3.7) | 12.0 (3.4) | 12.1 (3.5) |
Female, n (%) | 55 (71.4) | 48 (67.6) | 53 (76.8) | 156 (71.9) |
Male, n (%) | 22 (28.6) | 23 (32.4) | 16 (23.2) | 61 (28.1) |
Tanner Score, Median (IQR) | 2 (1 to 4) | 2 (1 to 4) | 2 (1 to 3) | 2 (1 to 4) |
Steroid Dose, n (%) <= 0.2 mg/kg | 37 (48.1) | 30 (42.3) | 32 (46.4) | 99 (45.6) |
Steroid Dose, n (%) >0.2 mg/kg | 40 (52.0) | 41 (57.8) | 37 (53.6) | 118 (54.4) |
Etanercept; Infliximab; Anakinra; Tocilizumab | 8 (10.5%) | 17 (23.9%) | 7 (10.1%) | 32 (14.8%) |
Prior fracture History (Yes), n (%) | 13 (17.1) | 9 (12.7) | 8 (11.6) | 30 (13.89) |